Your session is about to expire
← Back to Search
Antisense Oligonucleotide
Custirsen + Docetaxel for Non-Small Cell Lung Cancer
Phase 3
Waitlist Available
Research Sponsored by Achieve Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 months
Awards & highlights
Study Summary
The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival
Secondary outcome measures
Adverse events
Disease Control Rate
Duration of Disease Control
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Custirsen + DocetaxelExperimental Treatment2 Interventions
Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
Group II: DocetaxelActive Control1 Intervention
Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Custirsen
Not yet FDA approved
Docetaxel
FDA approved
Find a Location
Who is running the clinical trial?
Achieve Life SciencesLead Sponsor
34 Previous Clinical Trials
6,418 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger